Literature DB >> 26739648

Is Erwinase Necessary for all Children With ALL and Allergic Reactions to E. coli Asparaginase?

Ching-Hon Pui1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26739648      PMCID： PMC4755852          DOI： 10.1002/pbc.25876

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


× No keyword cloud information.
  15 in total

1.  Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.

Authors:  Jitesh D Kawedia; Chengcheng Liu; Deqing Pei; Cheng Cheng; Christian A Fernandez; Scott C Howard; Dario Campana; John C Panetta; W Paul Bowman; William E Evans; Ching-Hon Pui; Mary V Relling
Journal:  Blood       Date:  2011-11-23       Impact factor: 22.113

2.  Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

Authors:  L B Silverman; R D Gelber; V K Dalton; B L Asselin; R D Barr; L A Clavell; C A Hurwitz; A Moghrabi; Y Samson; M A Schorin; S Arkin; L Declerck; H J Cohen; S E Sallan
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

3.  Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.

Authors:  Lynda M Vrooman; Kristen E Stevenson; Jeffrey G Supko; Jane O'Brien; Suzanne E Dahlberg; Barbara L Asselin; Uma H Athale; Luis A Clavell; Kara M Kelly; Jeffery L Kutok; Caroline Laverdière; Steven E Lipshultz; Bruno Michon; Marshall Schorin; Mary V Relling; Harvey J Cohen; Donna S Neuberg; Stephen E Sallan; Lewis B Silverman
Journal:  J Clin Oncol       Date:  2013-01-28       Impact factor: 44.544

Review 4.  Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration.

Authors:  Ching-Hon Pui; Jun J Yang; Stephen P Hunger; Rob Pieters; Martin Schrappe; Andrea Biondi; Ajay Vora; André Baruchel; Lewis B Silverman; Kjeld Schmiegelow; Gabriele Escherich; Keizo Horibe; Yves C M Benoit; Shai Izraeli; Allen Eng Juh Yeoh; Der-Cherng Liang; James R Downing; William E Evans; Mary V Relling; Charles G Mullighan
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

5.  Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.

Authors:  Richard H Ko; Tamekia L Jones; David Radvinsky; Nathan Robison; Paul S Gaynon; Eduard H Panosyan; Ioannis A Avramis; Vassilios I Avramis; Joan Rubin; Lawrence J Ettinger; Nita L Seibel; Girish Dhall
Journal:  Cancer       Date:  2015-08-26       Impact factor: 6.860

6.  Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.

Authors:  Ajay Vora; Nick Goulden; Rachel Wade; Chris Mitchell; Jeremy Hancock; Rachael Hough; Clare Rowntree; Sue Richards
Journal:  Lancet Oncol       Date:  2013-02-07       Impact factor: 41.316

7.  Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia.

Authors:  Hsiu-Ju Yen; Wan-Hui Chang; Hsi-Che Liu; Ting-Chi Yeh; Giun-Yi Hung; Kang-Hsi Wu; Ching-Tien Peng; Yu-Hsiang Chang; Te-Kao Chang; Chih-Cheng Hsiao; Jiunn-Ming Sheen; Yu-Hua Chao; Tai-Tsung Chang; Shyh-Shin Chiou; Pei-Chin Lin; Shih-Chung Wang; Ming-Tsan Lin; Wan-Ling Ho; Yu-Chieh Chen; Der-Cherng Liang
Journal:  Pediatr Blood Cancer       Date:  2015-12-24       Impact factor: 3.167

8.  Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.

Authors:  Andrew E Place; Kristen E Stevenson; Lynda M Vrooman; Marian H Harris; Sarah K Hunt; Jane E O'Brien; Jeffrey G Supko; Barbara L Asselin; Uma H Athale; Luis A Clavell; Peter D Cole; Kara M Kelly; Caroline Laverdiere; Jean-Marie Leclerc; Bruno Michon; Marshall A Schorin; Jennifer J G Welch; Steven E Lipshultz; Jeffery L Kutok; Traci M Blonquist; Donna S Neuberg; Stephen E Sallan; Lewis B Silverman
Journal:  Lancet Oncol       Date:  2015-11-06       Impact factor: 41.316

9.  Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.

Authors:  Sujith Samarasinghe; Sunita Dhir; James Slack; Prasad Iyer; Rachel Wade; Rachel Clack; Ajay Vora; Nicholas Goulden
Journal:  Br J Haematol       Date:  2013-06-10       Impact factor: 6.998

Review 10.  Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase.

Authors:  Nicolas Boissel; Leonard S Sender
Journal:  J Adolesc Young Adult Oncol       Date:  2015-09       Impact factor: 2.223
View more
  2 in total

1.  Anticancer L-Asparaginase and Phytoactive Compounds From Plant Solanum nigrum Against MDR (Methicillindrug resistant) Staphylococcus aureus and Fungal Isolates.

Authors:  Ambreen Aisha; Saba Zahra; Imtiaz M Tahir; Asim Hussain; Naheed Bano; Alishbah Roobi; Nadia Afsheen; Yasir Saleem
Journal:  Dose Response       Date:  2022-04-27       Impact factor: 2.623

2.  L-asparaginase doses number as a prognostic factor in childhood acute lymphoblastic leukemia: A survival analysis study.

Authors:  Amanda Cabral Dos Santos; Julia Maria Bispo Dos Santos; Elisangela da Costa Lima; Marcelo Gerardin Poirot Land
Journal:  Cancer Rep (Hoboken)       Date:  2021-08-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.